RCT | Patient preference and treatment satisfaction with a port delivery system for Ranibizumab vs. intravitreal injections in patients with neovascular age-related macular degeneration.
30 Aug, 2022 | 12:06h | UTCCommentary: Port Delivery System Preferred Over Intravitreal Injection for Patients with nAMD – HCPLive
Commentary on Twitter
In the phase 3 Archway trial, mean overall treatment satisfaction scores were high in port delivery system & intravitreal injection arms; pts with neovascular AMD preferred treatment via the PDS with ranibizumab vs previous intravitreal injections https://t.co/NYf0aKpKaD
— JAMAOphthalmology (@JAMAOphth) August 25, 2022